 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- NBL-012 / CSPC Pharma
First-in-human study to evaluate the safety, tolerability, and pharmacokinetics of NBL-012, a novel anti-IL-23p19 monoclonal antibody, in healthy subjects (Poster Area) - Aug 5, 2024 - Abstract #EADV2024EADV_2649;
P1
NBL-012 displayed linear pharmacokinetics, a prolonged half-life supporting once-quarterly dosing, and superior exposure which may be advantageous for certain inflammatory indications requiring higher doses. These results support further clinical development of NBL-012.
- ||| NBL-012 / CSPC Pharma
Trial completion: A Study of NBL-012 in Healthy Chinese Subjects (clinicaltrials.gov) - Jul 20, 2022
P1, N=52, Completed, Sponsor: NovaRock Biotherapeutics, Ltd
These results support further clinical development of NBL-012. Active, not recruiting --> Completed
- ||| NBL-012 / CSPC Pharma
New P1 trial: A Study of NBL-012 in Healthy Chinese Subjects (clinicaltrials.gov) - Feb 28, 2022
P1, N=52, Active, not recruiting, Sponsor: NovaRock Biotherapeutics, Ltd